$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

$atos Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414067164 Filed on November 12, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$0.00	$3.426K	$76.60K
YoY Change	-100.0%	-95.53%	-27.45%
Cost Of Revenue	$0.00	$0.00	$25.94K
YoY Change	-100.0%	-100.0%	188.2%
Gross Profit	$0.00	$3.426K	$50.66K
YoY Change	-100.0%	-93.24%	-44.02%
Gross Profit Margin		100.0%	66.14%
Selling, General & Admin	$1.720M	$2.326M	$3.231M
YoY Change	-23.56%	-28.03%	376.57%
% of Gross Profit		67878.34%	6378.82%
Research & Development	-$750.0K	$923.2K	$321.1K
YoY Change	-302.7%	187.49%	-41.41%
% of Gross Profit		26945.97%	633.87%
Depreciation & Amortization	$180.0K	$24.64K	$27.17K
YoY Change	50.0%	-9.28%	171.65%
% of Gross Profit		719.29%	53.62%
Operating Expenses	$980.0K	$3.249M	$3.553M
YoY Change	-62.74%	-8.55%	189.73%
Operating Profit	-$980.0K	-$3.245M	-$3.502M
YoY Change	-62.45%	-7.33%	208.35%
Interest Expense	$0.00	$151.00	$1.00
YoY Change		15000.0%	-99.99%
% of Operating Profit
Other Income/Expense, Net		-$140.00
YoY Change
Pretax Income	-$3.330M	-$3.245M	-$3.502M
YoY Change	20.65%	-7.32%	206.27%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.810M	-$3.245M	-$3.502M
YoY Change	110.51%	-7.32%	206.27%
Net Earnings / Revenue		-94728.4%	-4571.78%
Basic Earnings Per Share
Diluted Earnings Per Share	-$41.50M	-$23.21M	-$38.89M
COMMON SHARES
Basic Shares Outstanding	24.56M shares	24.56M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.500M	$11.40M	$7.700M
YoY Change	34.92%	48.05%	1825.0%
Cash & Equivalents	$8.501M	$11.37M	$7.694M
Short-Term Investments
Other Short-Term Assets	$0.00	$300.0K	$600.0K
YoY Change	-100.0%	-50.0%	100.0%
Inventory	$9.276K	$0.00
Prepaid Expenses	$194.0K		$559.4K
Receivables	$298.0K	$0.00	$299.3K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$9.086M	$11.70M	$8.595M
YoY Change	34.37%	36.12%	855.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$136.7K	$200.0K	$443.3K
YoY Change	-16.21%	-54.88%	343.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$48.19K	$500.0K	$4.444M
YoY Change	32.23%	-88.75%
Total Long-Term Assets	$2.678M	$5.100M	$4.887M
YoY Change	-48.96%	4.36%	1.81%
TOTAL ASSETS
Total Short-Term Assets	$9.086M	$11.70M	$8.595M
Total Long-Term Assets	$2.678M	$5.100M	$4.887M
Total Assets	$11.76M	$16.80M	$13.48M
YoY Change	-2.04%	24.61%	136.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$513.0K	$400.0K	$31.13K
YoY Change	106.75%	1184.89%	-68.87%
Accrued Expenses	$254.1K	$393.7K	$1.400M
YoY Change	-13.95%	-71.88%	-26.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.214M	$1.500M	$1.942M
YoY Change	57.98%	-22.77%	-15.55%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.214M	$1.500M	$1.942M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.266M	$1.500M	$1.900M
YoY Change	61.0%	-21.05%	-17.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$35.17M		-$17.76M
YoY Change	71.44%
Common Stock	$24.56K		$17.45K
YoY Change	32.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.498M	$15.20M	$11.54M
YoY Change
Total Liabilities & Shareholders Equity	$11.76M	$16.80M	$13.48M
YoY Change	-2.04%	24.61%	136.53%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$5.810M	-$3.245M	-$3.502M
YoY Change	110.51%	-7.32%	206.27%
Depreciation, Depletion And Amortization	$180.0K	$24.64K	$27.17K
YoY Change	50.0%	-9.28%	171.65%
Cash From Operating Activities	-$2.720M	-$2.980M	-$2.740M
YoY Change	2.64%	8.76%	1726.67%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	-$100.0K	-$310.0K
YoY Change	-44.44%	-67.74%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$50.00K	-$100.0K	-$310.0K
YoY Change	-44.44%	-67.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-100.0K	150.0K	8.300M
YoY Change	-107.19%	-98.19%	1593.88%
NET CHANGE
Cash From Operating Activities	-2.720M	-2.980M	-2.740M
Cash From Investing Activities	-50.00K	-100.0K	-310.0K
Cash From Financing Activities	-100.0K	150.0K	8.300M
Net Change In Cash	-2.870M	-2.930M	5.250M
YoY Change	112.59%	-155.81%	1444.12%
FREE CASH FLOW
Cash From Operating Activities	-$2.720M	-$2.980M	-$2.740M
Capital Expenditures	-$50.00K	-$100.0K	-$310.0K
Free Cash Flow	-$2.670M	-$2.880M	-$2.430M
YoY Change	4.3%	18.52%	1520.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Security Deposit SecurityDeposit	36446	USD
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	393704	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	399478	USD
CY2014Q3	atos	Total Shares Authorized TotalSharesAuthorized	85000000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Use of Estimates:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Reclassifications:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The prior period deferred financing costs have been reclassified to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Certain prior period accrued expenses have been reclassified as accounts payable to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18574334	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18574334	shares
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	400000	USD
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	862500	shares
CY2012Q3	us-gaap	Share Price SharePrice	5.00
	atos	Warrants Issued During Period Acquisitions WarrantsIssuedDuringPeriodAcquisitions	325000	shares
	atos	Warrant Price WarrantPrice	2.3457
	us-gaap	Depreciation Depreciation	62849	USD
	us-gaap	Depreciation Depreciation	65678	USD
CY2013Q3	us-gaap	Depreciation Depreciation	27165	USD
CY2012Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.00
CY2014Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	150000	USD
CY2013Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0	USD
CY2014Q3	us-gaap	Prepaid Insurance PrepaidInsurance	36800	USD
CY2013Q4	us-gaap	Prepaid Insurance PrepaidInsurance	112517	USD
CY2014Q3	us-gaap	Supplies Supplies	42426	USD
CY2013Q4	us-gaap	Supplies Supplies	131204	USD
CY2014Q3	us-gaap	Deposit Assets DepositAssets	29500	USD
CY2014Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8000	USD
CY2014Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	429355	USD
CY2014Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	93665	USD
CY2014Q3	atos	Capitalized New Product Development Costs CapitalizedNewProductDevelopmentCosts	0	USD
CY2013Q4	atos	Capitalized New Product Development Costs CapitalizedNewProductDevelopmentCosts	15000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	114050	USD
CY2014Q3	atos	Allowance For Loss On Impairment Of Assets AllowanceForLossOnImpairmentOfAssets	158292	USD
CY2013Q4	atos	Allowance For Loss On Impairment Of Assets AllowanceForLossOnImpairmentOfAssets	158292	USD
CY2014Q3	us-gaap	Depreciation Depreciation	24643	USD
CY2013Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	4794853	USD
CY2013Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	0	USD
CY2013Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	105839	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	505059	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	110215	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	440539	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	433277	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	414957	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	393990	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2572334	USD
CY2014Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	566185	USD
CY2013Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	408362	USD
CY2014Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	102892	USD
CY2013Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	48232	USD
CY2014Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	13279	USD
CY2013Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	19883	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	361905	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	37425	USD
CY2013Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	72187	USD
CY2014Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	3426	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	223440	USD
	us-gaap	Cost Of Services CostOfServices	0	USD
CY2013Q3	us-gaap	Cost Of Services CostOfServices	25938	USD
	us-gaap	Selling Expense SellingExpense	743597	USD
CY2013Q3	us-gaap	Selling Expense SellingExpense	373418	USD
CY2014Q3	us-gaap	Selling Expense SellingExpense	282374	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	731258	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1856439	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4410	USD
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2014Q3	us-gaap	Cost Of Services CostOfServices	0	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	238669	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	585345	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	3426	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	50659	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	3426	USD
	us-gaap	Selling Expense SellingExpense	965383	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
	us-gaap	Cost Of Revenue CostOfRevenue	314562	USD
	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2013Q3	us-gaap	Cost Of Revenue CostOfRevenue	25938	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
	us-gaap	Gross Profit GrossProfit	270783	USD
	us-gaap	Gross Profit GrossProfit	37425	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	321111	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	923169	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6600819	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6280102	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2858027	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2043138	USD
	us-gaap	Operating Expenses OperatingExpenses	8297460	USD
	us-gaap	Operating Expenses OperatingExpenses	8880138	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	3552556	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	3248681	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8026677	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8842713	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3501897	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3245255	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	53	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	154	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	53	USD
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	11	USD
	us-gaap	Interest Expense InterestExpense	360	USD
	us-gaap	Interest Expense InterestExpense	2343	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	1	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	151	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8026984	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8844902	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3501845	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3245395	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8026984	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8844902	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-3501845	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-3245395	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14697221	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23860843	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15830033	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24537379	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	6033426	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.00
CY2014Q2	atos	Percentage Of Common Stock Outstanding PercentageOfCommonStockOutstanding	0.020	pure
CY2014Q2	atos	Entitled To Receive Worth Of Common Stock EntitledToReceiveWorthOfCommonStock	30.00
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9497658	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9497658	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7022201	shares
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9497658	shares
CY2014Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2014Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	11124251	USD
CY2013Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	6092161	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	105723	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	480007	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	464771	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	105894	USD
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1156395	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2282719	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2081669	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	740156	shares
	atos	Stock Issued During Period Shares Stock Options Exercised1 StockIssuedDuringPeriodSharesStockOptionsExercised1	160000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3464232	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1347215	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3190856	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.43
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.53
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.36
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.20
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.10
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.49
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.17
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M16D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y5M19D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M10D
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	282063	USD
	atos	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue	21540	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	69388	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	117267	USD
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	15856	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	108485	USD
CY2014Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	22728	shares
CY2013Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	24510	shares
CY2014Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	50000	USD
CY2013Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	50000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1187717	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	545115	USD
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	188763	USD
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	147399	USD
CY2014Q2	atos	Directors Compensation Paid DirectorsCompensationPaid	35000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	380977	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	228841	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	80870	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	386514	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-29051	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P2Y11M23D
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2117017	shares
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1596602	USD
	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	14002162	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	USD
	atos	Financing Fee From Public Offerig FinancingFeeFromPublicOfferig	-1078417	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	225000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	45867	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-71439	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	71099	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-43160	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-42512	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-37086	USD
	atos	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	32000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	200000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	545115	USD
	us-gaap	Profit Loss ProfitLoss	-8026984	USD
	us-gaap	Profit Loss ProfitLoss	-8844902	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	-144391	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	350536	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	191106	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	149493	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	205879	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	60753	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-39608	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-304626	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5774	USD
	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	402840	USD
	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	-208108	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	20300	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-11274	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6182060	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7836146	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	346007	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	102530	USD
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	54667	USD
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	184979	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-400674	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-287509	USD
	atos	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	12551098	USD
	atos	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	13155745	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12551098	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	13155745	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5968364	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5032090	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1725197	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7693561	USD
	us-gaap	Interest Paid InterestPaid	359	USD
	us-gaap	Interest Paid InterestPaid	2343	USD
	atos	Non Cash Reclassification Of Furniture And Equipment To Prepaid Expenses NonCashReclassificationOfFurnitureAndEquipmentToPrepaidExpenses	0	USD
	atos	Non Cash Reclassification Of Furniture And Equipment To Prepaid Expenses NonCashReclassificationOfFurnitureAndEquipmentToPrepaidExpenses	15000	USD
	atos	Common Stock Issued For Commitment Fee In Stock Purchase Agreement CommonStockIssuedForCommitmentFeeInStockPurchaseAgreement	2387250	USD
	atos	Common Stock Issued For Commitment Fee In Stock Purchase Agreement CommonStockIssuedForCommitmentFeeInStockPurchaseAgreement	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>NOTE 1: NATURE OF OPERATIONS</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was initially formed to develop and market medical devices that collect specimens for further testing. The Company’s fiscal year ends on December 31st.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In December 2011, the Company established The National Reference Laboratory for Breast Health, Inc., or the NRLBH, as a wholly-owned subsidiary. The NRLBH is a CLIA-certified laboratory which performs tests including nipple aspirate fluid (“NAF”) cytology testing and pharmacogenetics testing. The NRLBH is also developing other tests such as the NextCYTE test.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In September 2012, the Company acquired the assets of Acueity Healthcare, Inc. (“Acueity”). The purchased assets included intellectual property rights related to the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font>. No liabilities were assumed by Atossa and Atossa assumed no future financial obligations. In consideration for the assets, Atossa provided the following consideration to the shareholders of Acueity:  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 862,500</font> shares of common stock, valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.00</font> per share, and warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 325,000</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.00</font> per share, valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.3457</font> per warrant, using a Black-Scholes-Merton Valuation Technique. The acquired patents relate to intraductal diagnostic and therapeutic devices and methods of use. The Company did not, however, acquire an inventory of these diagnostic tools, manufacturing capabilities or any personnel to market and sell the tools. The Company cannot provide any assurance that it will be successful commercializing these tools.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plan will be successfully executed. The Company’s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	ATOSSA GENETICS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001488039
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	ATOS
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24564058	shares
CY2014Q3	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	162600	USD

Files In Submission

Name	View Source	Status
0001144204-14-067164-index-headers.html	Edgar Link	pending
0001144204-14-067164-index.html	Edgar Link	pending
0001144204-14-067164.txt	Edgar Link	pending
0001144204-14-067164-xbrl.zip	Edgar Link	pending
atos-20140930.xml	Edgar Link	completed
atos-20140930.xsd	Edgar Link	pending
atos-20140930_cal.xml	Edgar Link	unprocessable
atos-20140930_def.xml	Edgar Link	unprocessable
atos-20140930_lab.xml	Edgar Link	unprocessable
atos-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tex10-4logo.jpg	Edgar Link	pending
v392264_10q.htm	Edgar Link	pending
v392264_ex10-1.htm	Edgar Link	pending
v392264_ex10-2.htm	Edgar Link	pending
v392264_ex31-1.htm	Edgar Link	pending
v392264_ex31-2.htm	Edgar Link	pending
v392264_ex32-1.htm	Edgar Link	pending
v392264_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

2014 Q4 Form 10-Q Financial Statement

#000114420414067164 Filed on November 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS ATOSSA THERAPEUTICS, INC. Stock $atos

2014 Q4 Form 10-Q Financial Statement

#000114420414067164 Filed on November 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos